Company news

Palisade Bio, Inc. news in 2022

Palisade Bio, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

December 29, 2022

Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

December 15, 2022

Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

December 6, 2022

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

November 30, 2022

Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery

November 21, 2022

Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer

November 17, 2022

Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video

November 16, 2022

Palisade Bio Announces Reverse Stock Split

November 14, 2022

Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

Palisade Bio Announces Executive Leadership Transition

October 10, 2022

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022

September 28, 2022

Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 22, 2022

Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148

September 14, 2022

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

August 16, 2022

Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option

August 15, 2022

Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 14, 2022

Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

August 11, 2022

Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

July 31, 2022

Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

July 26, 2022

Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

June 28, 2022

Palisade Bio to Present at the 2022 BIO International Convention

June 6, 2022

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires

May 9, 2022

Palisade Bio Announces $2.0 Million Registered Direct Offering

May 5, 2022

Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

May 4, 2022

Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements

May 1, 2022

Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

March 21, 2022

Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update

March 17, 2022

Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

March 15, 2022

Decks in 2022